Clinical Trial:

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed or Refractory Hematologic Malignancies

This study is being done to test TTI-621 in humans. TTI-621 is a type of protein called a fusion protein which is similar to an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to hide from your body’s immune system. Blocking CD47 with TTI-621 may help your body’s immune system find and destroy the cancer cells. CD47 is also present on some normal cells including red blood cells and platelets. TTI-621 has been given to a small number of subjects with hematologic (blood) cancers through intravenous infusion.